Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
People with hypertension (high blood pressure in the arteries that supply the lungs, also known as PAH) have up to a two-fold reduction in pulmonary vascular resistance (PVR) when taking PAH.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Squeezing through tiny blood vessels may trigger melanoma cells to spread
2.
New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.
3.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
4.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
5.
T-DXd Reduces Residual Disease in Early Breast Cancer
1.
The Danger of Methemoglobinemia and How to Prevent It
2.
Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System
3.
Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy
4.
Exploring the Causes and Treatments of Cysts: A Comprehensive Guide
5.
Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
3.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge